Syntax Advisors, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Syntax Advisors, LLC
- $57.7 Million
- Q3 2023
A detailed history of Syntax Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Syntax Advisors, LLC holds 282 shares of REGN stock, worth $202,115. This represents 0.4% of its overall portfolio holdings.
Number of Shares
282
Previous 307
8.14%
Holding current value
$202,115
Previous $220,000
5.45%
% of portfolio
0.4%
Previous 0.34%
Shares
7 transactions
Others Institutions Holding REGN
# of Institutions
1,493Shares Held
83.2MCall Options Held
1.22MPut Options Held
1.5M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.68 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.05 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.37 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.51 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.08 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $76.8B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...